Management of stage T1 tumors of the bladder: International consensus panel

被引:169
作者
Nieder, AM
Brausi, M
Lamm, D
O'Donnell, M
Tomita, K
Woo, H
Jewett, MAS
机构
[1] SUNY Stony Brook, Dept Urol, Stony Brook, NY 11794 USA
[2] Estense S Agostino Hosp, Dept Urol, Modena, Italy
[3] BCG Oncol, Dept Urol, Phoenix, AZ USA
[4] Univ Iowa, Dept Urol, Iowa City, IA 52242 USA
[5] Univ Tokyo, Dept Urol, Tokyo 113, Japan
[6] Westmead Hosp, Dept Urol, Westmead, NSW 2145, Australia
[7] Univ Toronto, Princess Margaret Hosp, Univ Hlth Network, Dept Surg Oncol,Div Urol, Toronto, ON, Canada
关键词
D O I
10.1016/j.urology.2005.08.066
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
The International Consensus Panel on T1 bladder tumors markers reviewed the subject from a clinical perspective. From diagnosis to treatment decisions, what are the important issues in the management of a new patient? The assessment of prognostic factors for progression requires optimal resection and documentation. The role of immediate adjuvant intravesical chemotherapy after resection remains controversial. How often should the upper tract be assessed for tumor recurrence? The decision on whether to attempt bladder conservation with intravesical therapy or to perform a cystectomy is the most difficult issue in the management of superficial bladder cancer today. Finally, what therapies exist if initial intravesical bacille Calmette-Guerin fails to eradicate the disease or prevent recurrence? The panel thoroughly explored all these subjects and has made recommendations with supporting evidence.
引用
收藏
页码:108 / 125
页数:18
相关论文
共 109 条
[51]   Predictive value of p53 and pRb immunostaining in locally advanced bladder cancer treated with cystectomy [J].
Jahnson, S ;
Karlsson, MG .
JOURNAL OF UROLOGY, 1998, 160 (04) :1291-1296
[52]   MANAGEMENT OF LOCAL BACILLUS CALMETTE-GUERIN FAILURES IN SUPERFICIAL BLADDER-CANCER [J].
KLEIN, EA ;
ROGATKO, A ;
HERR, HW .
JOURNAL OF UROLOGY, 1992, 147 (03) :601-605
[53]   A randomized multicenter trial of adjuvant therapy in superficial bladder cancer: Transurethral resection only versus transurethral resection plus mitomycin C versus transurethral resection plus bacillus Calmette-Guerin [J].
Krege, S ;
Giani, G ;
Meyer, R ;
Otto, T ;
Rubben, H ;
Noll, F ;
Jakse, G ;
Melchior, HJ ;
Weissbach, L ;
Terhorst, B ;
Lenz, P ;
Faul, P ;
Sommerkamp, H ;
Kopper, B ;
Hautmann, R ;
Knebel, L ;
Eisenberger, F ;
Schaffner, W .
JOURNAL OF UROLOGY, 1996, 156 (03) :962-966
[54]   Recurrence and progression in stage T1G3 bladder tumour with intravesical bacille Calmette-Guerin (Danish 1331 strain) [J].
Kulkarni, JN ;
Gupta, R .
BJU INTERNATIONAL, 2002, 90 (06) :554-557
[55]   Adjuvant chemotherapy for superficial transitional cell bladder carcinoma: Long-term results of a European organization for research and treatment of cancer randomized trial comparing doxorubicin, ethoglucid and transurethral resection alone [J].
Kurth, K ;
Tunn, U ;
Ay, R ;
Schroder, FH ;
PavoneMacaluso, M ;
Debruyne, F ;
TenKate, F ;
DePauw, M ;
Sylvester, R ;
Essed, E ;
Caubergh, RV ;
Hoekstra, JW ;
deVoogt, HJ ;
Newling, DWW ;
deReijke, TM ;
Mensink, HJA ;
Groen, JM ;
Jakse, G ;
Leisinger, HJ ;
Richards, B ;
Adib, RA ;
Robinson, M ;
Denis, L ;
Bouffioux, C ;
Schulman, C ;
Carpentier, PJ .
JOURNAL OF UROLOGY, 1997, 158 (02) :378-384
[56]   Overexpression of p53 protein in a high-risk population of patients with superficial bladder cancer before and after Bacillus Calmette-Guerin therapy: Correlation to clinical outcome [J].
Lacombe, L ;
Dalbagni, G ;
Zhang, ZF ;
CordonCardo, C ;
Fair, WR ;
Herr, HW ;
Reuter, VE .
JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (10) :2646-2652
[57]   Bacillus Calmete-Guerin plus interferon-α2B intravesical therapy maintains an extended treatment plan for superficial bladder cancer with minimal toxicity [J].
Lam, JS ;
Benson, MC ;
O'Donnell, MA ;
Sawczuk, A ;
Gavazzi, A ;
Wechsler, MH ;
Sawczuk, IS .
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2003, 21 (05) :354-360
[58]   Efficacy and safety of bacille Calmette-Guerin immunotherapy in superficial bladder cancer [J].
Lamm, DL .
CLINICAL INFECTIOUS DISEASES, 2000, 31 :S86-S90
[59]   Maintenance bacillus Calmette-Guerin immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: A randomized Southwest Oncology Group study [J].
Lamm, DL ;
Blumenstein, BA ;
Crissman, JD ;
Montie, JE ;
Gottesman, JE ;
Lowe, BA ;
Sarosdy, MF ;
Bohl, RD ;
Grossman, HB ;
Beck, TM ;
Leimert, JT ;
Crawford, ED .
JOURNAL OF UROLOGY, 2000, 163 (04) :1124-1129
[60]   Low-dose BCG instillations in the treatment of stage T1 grade 3 bladder tumours:: Recurrence, progression and success [J].
Lebret, T ;
Gaudez, F ;
Hervé, JM ;
Barré, P ;
Lugagne, PM ;
Botto, H .
EUROPEAN UROLOGY, 1998, 34 (01) :67-72